DailyIQ
Last updated1 minute ago

ILMN·Illumina, Inc.

$240.54
+0.92 (+0.38%)
High
$248.30
Open
$241.50
Market Cap
36.18B
52W High
$250.06
Low
$239.46
P. Close
$240.54
P/E
43.86
52W Low
$88.00
Fwd P/E
40.38
DailyIQ Est.
$207.88
Inst. Ownership
55.8%
Short Interest
6.48%
Days to Cover
5.2
Technical Score (1D)
100
BUY
News Sentiment
69
BULLISH
Illumina’s latest earnings report delivered a clear upside surprise, with Q2 adjusted earnings per share of $1.31 beating the $1.23 consensus and revenue rising 9.5 % year‑over‑year to $1.16 billion. The earnings beat fuels the current rally, reinforcing the narrative that the company’s core genomics business is still expanding faster than analysts had expected. Because the market has already priced in a 7‑share split and a strong year‑to‑date gain, the upside from the earnings beat may translate into a short‑term lift in the share price as traders look for further upside. However, the same report highlighted insider cash‑outs of roughly $255 million, which could signal a potential valuation correction if the company’s growth trajectory stalls. In the next 1–10 trading days, investors should monitor how the market reacts to the earnings beat versus the insider cash‑out signal, as this will set the tone for the stock’s near‑term volatility. Watch for any guidance revisions in the upcoming earnings call, particularly regarding future revenue growth and margin expectations, as these will be critical in determining whether the current valuation remains justified. Additionally, keep an eye on any regulatory or supply‑chain developments that could impact Illumina’s ability to sustain its growth momentum.
Earnings Summary
Illumina is a global leader in genetic and genomic analysis, offering sequencing instruments, consumables, and kits that enable in‑depth genetic research and diagnostics across research centers, academic institutions, and healthcare providers, positioning it firmly within the diagnostics and research sector. In Q1 2025 the company reported EPS of $0.97 versus an estimate of $0.94 and revenue of $1.041 billion, while Q2 2026 saw EPS rise to $1.31 against an estimate of $1.23 and revenue climb to $1.159 billion from $1.152 billion, indicating a modest acceleration in both earnings and top line growth; the company has consistently beat estimates in the last two quarters, with EPS exceeding forecasts in both Q1 2025 and Q2 2026. Historically, Illumina has shown a steady YoY revenue growth trajectory, with Q2 2026 revenue up 5.5% from the same period in 2025, and EPS growth outpacing revenue, reflecting efficient cost management; the firm has also maintained a pattern of beating earnings estimates while occasionally missing revenue forecasts, underscoring its resilience in a competitive market. Recent news highlights include UBS upgrading Illumina to Buy and lifting its price target to $260, citing confidence in next‑generation sequencing platforms, and the company’s addition to the S&P 500, which will trigger passive fund rebalancing and likely increase institutional buying pressure; these developments suggest a near‑term positive bias for the stock, though insider sales by director Keith A. Meister may temper sentiment temporarily. Investors should watch for the Q3 2026 earnings release to confirm whether the raised FY26 revenue guidance of $4.60‑$4.64 billion is met, and monitor any updates on the Novacyt collaboration or the potential launch of neoantigen vaccine production that could drive future sequencing volumes, as these factors will be key to sustaining the company’s earnings trajectory.

EPS

EstBeatMiss
$0.88$1.00$1.12$1.25$1.37Q1'25Q2'26Q1'26
QtrEstActual+/−
Q1'26$1.06 - -
Q2'26$1.23$1.31+6.8%
Q1'25$0.94$0.97+3.3%

Revenue

EstBeatMiss
$1.0B$1.1B$1.1B$1.1B$1.2BQ1'25Q2'26Q1'26
QtrEstActual+/−
Q1'26$1.1B - -
Q2'26$1.2B$1.2B+0.6%
Q1'25 - $1.0B -

Market Data

ILMN Stock Snapshot

BUY100/100
$240.54+$0.92 (0.4%)
Market cap
36.18B
P/E ratio
43.9
Day range
$239.46 – $248.30
News sentiment
69/100 · Bullish
Analyst target
$202.65 (-15.8%)
Consensus
Buy · 28 analysts
52-week range+173.3% off low · -3.8% from high
$88.00$250.06
Price $240.54 DailyIQ Est. $207.88

Momentum is working in ILMN's favour - the indicator set leans bullish rather than mixed. In Healthcare, names this size usually take direction from sector flows before company-level news.

Behaviour On Record

What ILMN's own history says about today's numbers

Realized volatility (21d)
52.6% 83rd pct
Below its peak
-52.2%
vs 200-day average
+56.2%
Up days (1y)
52%

Illumina, Inc. is currently running 52.6% annualised volatility over the last 21 sessions. Measured against ILMN's own 13 years of daily returns rather than a market-wide average, that is the 83rd percentile elevated for this stock, against a typical reading of 36.4%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

ILMN is trading -52.2% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -34.3%, and the deepest was -60.1% in 2023. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +56.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 100th percentile a wider gap than this stock usually carries. Over the past year ILMN closed higher on 52% of sessions, and it is currently 1 session into a rising streak.

On September specifically: over 13 years of records, ILMN finished the month higher 5 of 13 times, with a median return of -3.8% and an average of -2.2%. Its strongest month historically has been January at +4.5% on average, its weakest February at -3.4%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: ILMN has opened more than 2% away from the prior close in 172 of 3,267 sessions (5.3% of the time), with the largest gaps running +8.1% and -10.2%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 3,268 daily closes between 2013-09-23 and 2026-09-21, split-adjusted, recomputed daily. Percentiles are against ILMN's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of ILMN's sector?

Illumina, Inc. sits in the Health Care sector, currently ranked 5th of 11 GICS sectors by relative-strength rotation score (improving).

Sector rank
#5 of 11
Sector state
Improving
Sector rotation score
80

Options Market

What is the options market pricing for ILMN?

CallsPuts

For Illumina, Inc.'s nearest expiry (2026-10-16, 25 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.43), with at-the-money implied volatility around 52.6%. The options market is pricing roughly a ±13.4% move by that expiry — a range of about $209.33–$273.93.

Put/call ratio (2026-10-16)
0.43
ATM implied volatility
52.6%
Total open interest
2,564
Expected move by 2026-10-16
±13.4% ($209.33–$273.93)

Analyst Rating Changes

Are analysts turning bullish or bearish on ILMN?

UBS most recently upgraded Illumina, Inc. to Buy on Sep 9, 2026 with a price target of $260 (from $135). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.

Latest action
UBSBuy
90-day upgrades
1
90-day downgrades
0
Net rating momentum
+1
DateFirmActionRatingPrice target
Sep 9, 2026UBSUpgradeNeutral → Buy$135 → $260
Sep 3, 2026Argus ResearchMaintainedBuy$180 → $235
Aug 3, 2026Canaccord GenuityMaintainedHold$190 → $205
Aug 3, 2026CitigroupMaintainedSell$95 → $113
Aug 3, 2026Piper SandlerReiteratedOverweight$200 → $225
Jul 31, 2026RBC CapitalMaintainedOutperform$170 → $230
Jul 31, 2026JP MorganMaintainedOverweight$220 → $230
Jul 31, 2026TD CowenMaintainedHold$192 → $210
Jul 31, 2026GuggenheimMaintainedBuy$200 → $226
Jul 31, 2026StifelMaintainedBuy$155 → $225
Jul 31, 2026BarclaysMaintainedUnderweight$145 → $160
Jul 17, 2026Leerink PartnersMaintainedOutperform$175 → $210

ILMN Competitive Positioning

Illumina, Inc. (ILMN) is tracked alongside these names in Diagnostics & Research on DailyIQ — ranked by market cap, with today's move alongside.